

The undersigned Sara Carucci, aware of the criminal consequences provided for by law (Article 76 of Presidential Decree 445/2000) in case of false statements, pursuant to art. 46 and 47 of the Presidential Decree n. 445/2000,

DECLARES

under her own responsibility, the following curriculum vitae and publications:

## Curriculum Vitae

SARA CARUCCI, MD, PhD  
Nationality: Italian

Work Address:  
Child and Adolescent Neuropsychiatry Unit  
"A. Cao" Pediatric Hospital,  
Via Edward Jenner 18  
09121 Cagliari, Italy

email: sara.carucci@unica.it

## Current Position

- **Associate Professor of Child and Adolescent Neuropsychiatry**, Department of Medical Science and Public Health, University of Cagliari Italy, from October 2024
- **Head of the Child and Adolescent Neuropsychiatry Unit "A. Cao"** Pediatric Hospital, ASL Cagliari, Italy, from October 2024
- **Senior Consultant in Child and Adolescent Neuropsychiatry**, "A. Cao" Pediatric Hospital, ASL Cagliari, Italy

## Education and Professional Qualifications

Year	Degree	Name of Granting Institution	Location
2024	Associate Professor of Child and Adolescent Psychiatry	University of Cagliari	Cagliari- Italy
2022	Contract Professor of Child and Adolescent Psychiatry	University of Cagliari	Cagliari- Italy
2016	Honorary Lecturer in Child and Adolescent Psychiatry	University of Cagliari	Cagliari- Italy
2016	PhD in Neuroscience	University of Cagliari	Cagliari- Italy
2009	Specialization in Child Neurology and Psychiatry	University of Cagliari	Cagliari- Italy
2009	6 months Internship in Child and Adolescent Psychiatry	University of Nottingham	Nottingham-UK
2004	Degree in Medicine and Surgery	University of Cagliari	Cagliari- Italy

## Experience/Current and Previous Positions (\*in chronological order)

From-To	Title	Address (Institute Name, Location)
2005-2010	General Practitioner (substitute)	Different General Practitioner ambulatory sites, Italy Total hours worked: 500
2010 - 2015	Temporary Consultant in Child and Adolescent Neuropsychiatry	Child and Adolescent (C&AP) Neuropsychiatry Unit Centre for Pharmacological Therapies in C&AP "G. Macciotta" site, Cagliari University Hospital Via Ospedale 119 Cagliari
2015 - 2020	Consultant in Child and Adolescent Neuropsychiatry	Child and Adolescent Neuropsychiatry Unit "A. Cao" Pediatric Hospital, "G. Brotzu" Hospital Trust, Via Jenner Cagliari, Italy
2020 – oct 2024	Senior Consultant in Child and Adolescent Neuropsychiatry	Child and Adolescent Neuropsychiatry Unit "A. Cao" Pediatric Hospital, Via Jenner Cagliari, Italy
Oct 2024 - current	Head of the Child and Adolescent Neuropsychiatry Unit	Child and Adolescent Neuropsychiatry Unit "A. Cao" Pediatric Hospital, Via Jenner ASL Cagliari, Italy
	Associate Professor of Child and Adolescent Neuropsychiatry	Department of Medical Science and Public Health University of Cagliari

## Teachings in the Faculty of Medicine and Health Area Graduate Schools, University of Cagliari

- Child and Adolescent Neuropsychiatry (Child and Adolescent Neuropsychiatry Resident program)
- Child and Adolescent Neuropsychiatry (General Pediatrics in Course Medicine and Surgery)
- Child and Adolescent Neuropsychiatry (Course Physiotherapy)
- Child and Adolescent Neuropsychiatry (Course Professional Education)
- Child and Adolescent Neuropsychiatry (Course Psychiatric Rehabilitation Techniques)
- Child and Adolescent Neuropsychiatry (Master Degree in Rehabilitation Sciences of Health Professions)
- Child and Adolescent Neuropsychiatry (Course Neurophysiopathology techniques)
- Etiopathogenetic mechanisms of CNS diseases and Diagnosis and intervention in developmental psychopathology (Specialization in Health Psychology)
- Child and Adolescent Neuropsychiatry (Course for educational support activities for students with disabilities)

## Teaching activities outside the academic field

- Training project in Child and Adolescent Neuropsychiatry (ADHD) for USSL Vicenza (December 2024)
- Training project in Child and Adolescent Neuropsychiatry (ADHD) for USSL Toscana (July 2022)
- Training project in Child and Adolescent Neuropsychiatry (Safety and tolerability of psychotropic drugs in child and adolescent psychiatry) for USSL Catania (October 2019)
- Training course for nursing staff “nursing management of psychiatric emergencies in developmental age” (Cagliari, November 2019; January 2012)
- Master School in Clinical Practice on ADHD (Cagliari, 2014)

## Participation as a SPEAKER/Member of the Organization Committee in international conferences and high professional qualification titles

- EFGCP Annual Paediatric Conference. Speaker and Chair of the session “Neuro Health”; Presentation title: Paediatric irritability: from definition and Assessment to treatment (Bruxelles 22 October 2024). EFGCP (European Forum for Good Clinical Practice)
- Eunethydis Annual Meeting 2024. Member of the Organization Committee and chair of the session “ADHD in Italy: the local perspective” (Cagliari 9 October 2024). Eunethydis (EUropean NETwork HYperactivity DISorders)
- Multistakeholder Meeting on Pediatric Irritability 2024. Member of the Organization Committee and participant of the round table (Nice 18-19 March 2024). Connect 4 children (c4c network).
- Eunethydis Webinar Series 2023-2024. Presentation title: Efficacy and safety of ADHD medications in different populations. Eunethydis (EUropean NETwork HYperactivity DISorders)
- LEADER and Developer of the short course “Issues in Adolescent clinical trials” within the Collaborative Network for European Clinical Trials for Children’ c4c supported by IMI-2 and Horizon 2020 (2023-2024)
- Eunethydis Annual Meeting 2023. Presentation title: National ADHD strategies (Montpellier 18 Sept 2023). Eunethydis
- *9th World Congress on ADHD*. Presentation title: The results from the ADDUCE project (Amsterdam 18 may 2023)
- LEADER of the PSYCHIATRY EXPERT GROUP within the Collaborative Network for European Clinical Trials for Children’ c4c supported by IMI-2 and Horizon 2020 (from 2022 to date)
- ECNP School of Child and Adolescent Neuropsychopharmacology. *The management of adverse effects: the ADHD medications (Venice, 28 March 2022)* and chair of clinical case sessions. European College of NeuroPsychopharmacology
- ECNP School of Child and Adolescent Neuropsychopharmacology. Presentation title: *Safety of ADHD medications. Results from the ADDUCE project. (Venice, 9 April 2018)*. European College of NeuroPsychopharmacology
- 17° International Conference European Society Child & Adolescent Psychiatry ESCAP. Presentation title: *The impact of long-term methylphenidate on Growth (weight, height, BMI), pubertal maturation, and bone age (Geneva, 11 July 2017)*. European Society for Child and Adolescent Psychiatry

- ECNP School of Child and Adolescent Neuropsychopharmacology. Presentation title: *Safety of ADHD medications. Results from the ADDUCE project. (Venice, 3 April 2017)*. European College of NeuroPsychopharmacology
- 4° International ADHD Congress: Eunethydis. Symposium. Presentation title: *Growth (weight, height) and pubertal maturation and bone age. (Berlin, 17 October 2016)*. Eunethydis Network
- XXVII SINPIA Congress Satellite Seminar. International views in child and adolescent psychopathology. Presentation title: *Safety of ADHD medications: the results of the ADDUCE study (Cagliari 10-11 October 2016)*. University of Cagliari
- 27° International Congress of the European College of NeuroPsychopharmacology (ECNP). Presentation title: *Improving the long-term outcomes of ADHD (Berlin, 18 October 2014)*.
- Symposium “III Symposium of the Mediterranean Society of Mental Health. Summer School on Bipolar Disorders”. Presentation title: *ADHD and Bipolar Disorders. (Cagliari, 9 May 2013)*. University of Cagliari
- IV World Congress on ADHD “from childhood to adult disease”. Presentation title: *Social responsiveness and deficits in facial emotion identification in ADHD. (Milan, 8 June 2013)*. World Federation ADHD
- International conference Meeting of Minds IV “Optimizing the management and treatment of ADHD”. Presentation title: *A challenging trilogy: ASD & ADHD & an explosive disorder (Zurich, 22-23 March 2012)*. Shire ADHD Educational Institute.
- Eunethydis 1st International ADHD Conference. Presentation title: *ADHD as predictive factor of poor outcome in Pediatric Bipolar Disorder (Amsterdam 26-28 May 2010)* Eunethydis Network.

## Clinical research projects

Start Date	Role and study design	Project
2022	Principal investigator Observational prospective longitudinal study	<i>Dynamics Of Affect Modulation In Neurodevelopmental Disorders - Dynamond</i>
2022	Co-Principal investigator Observational prospective longitudinal study	<i>“Neuropsychological characterization of ADHD vs ASD children and adolescents” (CN-DAAS)</i>
2022	Principal investigator Observational prospective longitudinal study	<i>Identifying Neurobiological Markers in Obsessive–Compulsive Disorder: A Cross-Sectional Study in Subgroups of Differing Phenotype</i>
2020	Site Investigator Observational retrospective and prospective longitudinal study	<i>Impact of the COVID-19 Pandemic on Child and Adolescent Psychiatric Emergencies</i>
2020	Site Investigator Observational retrospective study	<i>Pandemic-Related Emergency Psychiatric Presentations for Self-Harm of Children and Adolescents in 10 Countries (PREP-Kids): A Retrospective International Cohort Study</i>
2020	Co-Investigator	<i>Collaborative Network for European Clinical Trials for Children’ (<a href="https://conect4children.org/">https://conect4children.org/</a>)</i>
2016	Site Investigator	<i>An international clinical study of ability and</i>

	Observational study	<i>disability in autism spectrum disorder using the who-icf framework icf</i>
2013- 2020	Sub-investigator Phase II	<i>Multidisciplinary approaches to translational research in Conduct Syndromes (MATRICS): Drug Treatments for aggressive behaviour in Conduct Disorder (FP7-GA 603016; <a href="http://matrics-project.eu/">http://matrics-project.eu/</a>)</i>
2013	Co-investigator Non randomized CT	<i>Social Responsiveness and Deficits In Facial Emotion Identification In ADHD</i>
2012	Co-investigator Phase IV	<i>Paediatric European Risperidone Studies (PERS)”. European registrative program for off-label drugs (FP7 241959; <a href="http://www.pers-project.com/">http://www.pers-project.com/</a>)</i>
2011	CO-investigator Phase IV	<i>Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE). Adverse Drug Reaction Research: Long term effects in children and young adults of methylphenidate in the treatment of ADHD (FP7-GA 260576; <a href="http://www.adhd-adduce.org/page/view/2/Home">http://www.adhd-adduce.org/page/view/2/Home</a>)</i>
2010	Co- Principal Investigator Phase IIb	<i>A Randomised, Double-Blind, Multicentre, Placebo Controlled Efficacy Study of a specific Omega-3/6 combination in children aged 6 to 12 with mild to moderate (ADHD-I) (unrestricted research grant by Vifor Pharma)</i>

## Industry sponsored registrative clinical trials

Year	Phase	Indication
2023	II	<i>P21-01: An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children and adolescents with Autism Spectrum Disorders</i>
2022	II	<i>A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder</i>
2022	II	<i>A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (ASD) Sponsor ACADIA</i>
2019	III	<i>A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 years old) With Schizophrenia. (Protocol 331-10-234) Sponsor Otsuka 2019-2021</i>
2019	III	<i>A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia (Protocol 331-10-236) Sponsor Otsuka 2019-2021</i>
2018	IIb	<i>A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for Suicide. (Protocol ESKETINSUI2002) Sponsor: Janssen-Cililag 2018-2021</i>
2017	III	<i>Long-term, open-label, flexible-dose, extension study of vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD)from 7 to 18 years of age. (Protocol ADVANCE 12712A) Sponsor Lundbeck 2016-2019</i>

2016	III	<i>Interventional, randomised, double-blind, placebo- controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major depressive disorder (MDD) (Protocol ADVANCE 12709) Sponsor Lundbeck 2016-2019</i>
2016	III	<i>Interventional, randomised, double-blind, placebo- controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 12 to 17 years, with Major depressive disorder (MDD) (Protocol ADVANCE 12710A) Sponsor Lundbeck 2016-2019</i>
2012	IV	<i>Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine in Children and Adolescents with ADHD (Protocol SPD489-404) Sponsor: Shire 2011-2015</i>
2011	IIIb	<i>Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine to Atomoxetine in ADHD Children and Adolescents Who Have Had an Inadequate Response to Methylphenidate. (Protocol SPD489-317) Sponsor: Shire 2011-2012</i>
2009	III	<i>Randomized, Double Blind, Multicentre, Parallel-group Placebo and Active Controlled, dose Optimisation safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents with ADHD (Protocol SPD489-325) Sponsor: Shire 2008-2011</i>
2009	III	<i>Double-Blind, Placebo-Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents with ADHD (Protocol SPD489-326) Sponsor: Shire 2008-2011</i>
2006	III	<i>Double-Blind Placebo Controlled Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents with ADHD and ODD (Protocol: B4Z-IT-LYCY) Sponsor: Eli Lilly 2004-2006</i>

### **Membership in scientific societies:**

- *Società Italiana di Neuropsichiatria dell'Infanzia e Adolescenza (SINPIA) in the position of Secretary of the Psychiatric section;*
- *Società Italiana di NeuroPsicoFarmacologia (SINPF) in the position of Coordinator of the group of Psychopharmacology in the developmental age*
- *European ADHD Guidelines Group (EAGG)*
- *The European Network for Hyperkinetic Disorders (EUNETHYDIS)*
- *The European College of Neuropsychopharmacology (ECNP)*

### **Editorial boards:**

- *Frontiers in Child and Adolescent Psychiatry (David Coghill): Associate Editor*
- *Medico e Bambino (Federico Marchetti): Member of Editorial board*

## Reviewer for peer reviewed journals:

- *Neuroscience and Biobehavioural Reviews*;
- *Journal of Attention Disorders*,
- *Acta Paediatrica*;
- *Child and Adolescent Psychiatry and Mental Health*;
- *Journal of the American Academy of Child and Adolescent Psychiatry*;
- *Lancet Psychiatry*
- *Evidence Based Mental Health*

## Publications

1. Congiu P, Gagliano A, **Carucci S**, Lanza G, Ferri R, Puligheddu M. REM sleep atonia in patients with pediatric acute-onset neuropsychiatric syndrome: implications for pathophysiology. *J Clin Sleep Med*. 2025 May 1;21(5):757-764. doi: 10.5664/jcsm.11544.
2. Westwood SJ, Aggensteiner PM, Kaiser A, Nagy P, Donno F, Merkl D, Balia C, Goujon A, Bousquet E, Capodiferro AM, Derks L, Purper-Ouakil D, **Carucci S**, Holtmann M, Brandeis D, Cortese S, Sonuga-Barke EJS; European ADHD Guidelines Group (EAGG). Neurofeedback for Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. *JAMA Psychiatry*. 2025 Feb 1;82(2):118-129. doi: 10.1001/jamapsychiatry.2024.3702.
3. **Carucci S**, Di Martino A, Castellanos Fx, Masi G, Banaschewski T, Coghill D, Moreno C, Cortese S. Professor Alessandro Zuddas' Impact and Legacy: The Influential Networking and Human Connection Skills of a Passionate Scientist, Clinical Academic, and Pioneer in Child and Adolescent Psychopharmacology. *J Child Adolesc Psychopharmacol*. 2024 Oct 15. doi: 10.1089/cap.2024.0101.
4. Davico C, Marcotulli D, Abbracciavento G, Anfosso T, Apicella M, Averna R, Bazzoni M, Calderoni D, Cammisia L, Carta A, **Carucci S**, Cozzi G, Di Santo F, Fazzi E, Lux C, Narducci C, Nobili L, Onida I, Pisano T, Raucci U, Sforzi I, Siri L, Sotgiu S, Tavano S, Terrinoni A, Uccella S, Vicari S, Zanus C, Vitiello B; Italian Covid-Child and Adolescent Psychiatric Emergencies Study Group. COVID-19 Pandemic School Disruptions and Acute Mental Health in Children and Adolescents. *JAMA Netw Open*. 2024 Aug 1;7(8):e2425829. doi: 10.1001/jamanetworkopen.2024.25829.
5. Gagliano A, Costanza C, Di Modica I, **Carucci S**, Donno F, Germanò E, Abbate Cs, Roccella M, Vetri L. Neurodevelopmental Disorders and Suicide: A Narrative Review. *J Clin Med*. 2024 Mar 12;13(6):1627. doi: 10.3390/jcm13061627.
6. **Carucci S**, Zuddas A, Lampis A, Man Kkc, Balia C, Buitelaar J, Danckaerts M, Dittmann Rw, Donno F, Falissard B, Gagliano A, Garas P Häge A, Hollis C, Inglis Sk, Konrad K, Kovshoff H, Liddle E, Mccarthy S, Neubert A, Nagy P, Rosenthal E, Sonuga-Barke Ejs, Wong Ick, Banaschewski T, Coghill D, On Behalf Of The Adduce Consortium. The impact of methylphenidate on pubertal maturation and bone age in ADHD children and adolescents: results from the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) project. *J Atten Disord*. 2024; 28(5):722-739. doi: 10.1177/10870547241226726.
7. Häge A, Man Kkc, Inglis Sk, Buitelaar J, **Carucci S**, Danckaerts M, Dittmann Rw, Falissard B, Garas P, Hollis C, Konrad K, Kovshoff H, Liddle E, Mccarthy S, Neubert A, Nagy P, Rosenthal E, Sonuga-Barke Ejs, Zuddas A, Wong Ick, Coghill D, Banaschewski T. Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study. *J Atten Disord*. 2024 Mar;28(5):699-707. doi: 10.1177/10870547241232337.
8. Cortese S, Purper-Ouakil D, Apter A, Arango C, Baeza I, Banaschewski T , Buitelaar J, Castro-Fornieles J, Coghill D, Cohen D, Correll Cu, Grünblatt E, Hoekstra Pj, James A, Jeppesen P,.... **Carucci S**...., Moreno C. Psychopharmacology in Children and Adolescents: unmet needs and opportunities. *Lancet Psychiatry*. 2024; 11(2):143-154. doi: 10.1016/S2215-0366(23)00345-0.

9. Masi G, **Carucci S**, Muratori P, Balia C, Sesso G, Milone A. Contemporary diagnosis and treatment of conduct disorder in youth. *Expert Rev Neurother.* 2023 Oct 19:1-20. doi: 10.1080/14737175.2023.2271169.
10. Carnovale C, Battini V, Santoro C, Riccio MP, **Carucci S**, Nobile M, Formisano P, Bravaccio C, Zuddas A, Clementi E, Pozzi M, Pisano S. Umbrella Review: Association Between Antipsychotic Drugs and Metabolic Syndrome Hallmarks in Children and Adolescents. *J Am Acad Child Adolesc Psychiatry.* 2023 Jun 23:S0890-8567(23)00317-9. doi: 10.1016/j.jaac.2023.04.018.
11. Fellendorf FT, Caboni E, Paribello P, Pinna M, D'Aloja E, **Carucci S**, Pinna F, Reininghaus EZ, Carpiniello B, Manchia M. Pharmacological Treatment of Bipolar Depression: A Review of Observational Studies. *Pharmaceuticals (Basel).* 2023 Jan 25;16(2):182. doi: 10.3390/ph16020182
12. Man KKC, Häge A, Banaschewski T, Inglis SK, Buitelaar J, **Carucci S**, Danckaerts M, Dittmann RW, Falissard B, Garas P, Hollis C, Konrad K, Kovshoff H, Liddle E, McCarthy S, Neubert A, Nagy P, Rosenthal E, Sonuga-Barke EJS, Zuddas A, Wong ICK, Coghill D; ADDUCE Consortium. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. *Lancet Psychiatry.* 2023 May;10(5):323-333. doi: 10.1016/S2215-0366(23)00042-1.
13. Paribello P, Carpiniello B, Murgia R, Porcheddu AA, El-Kacemi S, Pinna M, Contu M, Costa G, Barbarossa R, Sanna E, et al. Identifying Neurobiological Markers in Obsessive–Compulsive Disorder: A Study Protocol for a Cross-Sectional Study in Subgroups of Differing Phenotype. *Applied Sciences.* 2023; 13(12):7306. <https://doi.org/10.3390/app13127306>
14. Donno F, Balia C, Boi J, Manchia M, Zuddas A, **Carucci S**. Social and executive functioning in individuals with autism spectrum disorder without intellectual disability: The case–control study protocol of the CNeSA study. *Frontiers in Child and Adolescent Psychiatry* (2023) volume 2 <https://www.frontiersin.org/articles/10.3389/frcha.2023.1149244>. DOI=10.3389/frcha.2023.1149244
15. Gagliano A, Murgia F, Capodiferro AM, Tanca MG, Hendren A, Falqui SG, Aresti M, Comini M, **Carucci S**, Cocco E, Lorefice L, Roccella M, Vetri L, Sotgiu S, Zuddas A, Atzori L. 1H-NMR-Based Metabolomics in Autism Spectrum Disorder and Pediatric Acute-Onset Neuropsychiatric Syndrome. *J Clin Med.* 2022 Nov 1;11(21):6493. doi: 10.3390/jcm11216493.
16. **Carucci S**, Romaniello R, Demuru G, Curatolo P, Grelloni C, Masi G, Liboni F, Mereu A, Contu P, Lamberti M, Gagliano A, Zuddas A. Omega-3/6 supplementation for mild to moderate inattentive ADHD: a randomised, double-blind, placebo-controlled efficacy study in Italian children. *Eur Arch Psychiatry Clin Neurosci.* 2022 Jun 7. doi: 10.1007/s00406-022-01428-2.
17. Wong Bh, Vaezinejad M, Plener PI, Mehdi T, Romaniuk L, Barrett E, Hussain H, Lloyd A, Tolmac J, Rao M, Chakrabarti S, **Carucci S**, Moghraby Os, Elvins R, Rozali F, Skouta E, Mcnicholas F, Baig B, Stevanovic D, Nagy P, Davico C, Mirza H, Tufan E, Youssef F, Meadowcroft B, Ougrin D. Lockdown stringency and paediatric self-harm presentations during covid-19 pandemic: retrospective cohort study. *BJPsych Open.* 2022 Mar 24;8(2):e75.
18. **Carucci S**, Narducci C, Bazzoni M, Balia C, Donno F, Gagliano A, Zuddas A. Clinical characteristics, neuroimaging findings, and neuropsychological functioning in attention-deficit hyperactivity disorder: Sex differences. *J Neurosci Res.* 2022 Mar 15. doi: 10.1002/jnr.25038.
19. Balia C\*, **Carucci S\***, Milone A, Romaniello R, Valente E, Donno F, Montesanto A, Brovedani P, Masi G, Glennon Jc, Coghill D, Zuddas A, The Matrics Consortium. Neuropsychological characterization of aggressive behavior in children and adolescents with cd/odd and effects of single doses of medications: the protocol of the matrices\_WP6-1 study. *Brain Sci.* 2021 Dec 11;11(12):1639. doi: 10.3390/brainsci11121639.
20. Gagliano A, Puligheddu M, Ronzano N, Congiu P, Tanca Mg, Cursio I, **Carucci S**, Sotgiu S, Grossi E, Zuddas A. Artificial neural networks analysis of polysomnographic and clinical features in pediatric acute-onset neuropsychiatric syndrome (pans): from sleep alteration to "brain fog". *Nat Sci Sleep.* 2021 Jul 23;13:1209-1224. doi: 10.2147/NSS.S300818.

21. Murgia F, Gagliano A, Tanca Mg, Or-Geva N, Hendren A, **Carucci S**, Pintor M, Cera F, Cossu F, Sotgiu S, Atzori L, Zuddas A. Metabolomic characterization of pediatric acute-onset neuropsychiatric syndrome (PANS). *Front Neurosci*. 2021 May 28;15:645267. doi: 10.3389/fnins.2021.645267.
22. Ougrin D, Wong Bh, Vaezinejad M, Plener Pl, Mehdi T, Romaniuk L, Barrett E, Hussain H, Lloyd A, Tolmac J, Rao M, Chakrabarti S, **Carucci S**, Moghraby Os, Elvins R, Rozali F, Skouta E, Mcnicholas F, Kuruppuaracchi N, Stevanovic D, Nagy P, Davico C, Mirza H, Tufan E, Youssef F, Meadowcroft B, Landau S. Pandemic-related emergency psychiatric presentations for self-harm of children and adolescents in 10 countries (PREP-KIDS): a retrospective international cohort study. *Eur Child Adolesc Psychiatry* 2021 doi: 10.1007/s00787-021-01741-6. Epub ahead of print.
23. **Carucci S**, Balia C, Gagliano A, Lampis A, Buitelaar Jk, Danckaerts M, Dittmann Rw, Garas P, Hollis C, Inglis S, Konrad K, Kovshoff H, Liddle Eb, Mccarthy S, Nagy P, Panei P, Romaniello R, Usala T, Wong Ick, Banaschewski T, Sonuga-Barke E, Coghill D, Zuddas A; Adduce Consortium. Long term methylphenidate exposure and growth in children and adolescents with adhd. a systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2021; 120:509-525. doi: 10.1016/j.neubiorev.2020.09.031.
24. **Carucci S**. Editorial: two centimeters more or less. how much does it matter to an adolescent or a young adult with attention-deficit/hyperactivity disorder? *J Am Acad Child Adolesc Psychiatry*. 2020; 59(12):1318-1320. doi:10.1016/j.jaac.2020.10.002.
25. Gagliano A, Galati C, Ingrassia M, Ciuffo M, Alquino Ma, Tanca Mg, **Carucci S**, Zuddas A, Grossi E. Pediatric acute-onset neuropsychiatric syndrome: a data mining approach to a very specific constellation of clinical variables. *J Child Adolesc Psychopharmacol*. 2020; 30(8):495-511. doi: 10.1089/cap.2019.0165.
26. Murgia F, Gagliano A, Tanca Mg, Or-Geva N, Hendren A, **Carucci S**, Pintor M, Cera F, Cossu F, Sotgiu S, Atzori L, Zuddas A. Metabolomic characterization of pediatric acute-onset neuropsychiatric syndrome (PANS). *Front Neurosci*. 2021; 15:645267.
27. Krinzinger H, Hall Cl, Groom Mj, Ansari Mt, Banaschewski T, Buitelaar Jk, **Carucci S**, Coghill D, Danckaerts M, Dittmann Rw, Falissard B, Garas P, Inglis Sk, Kovshoff H, Kochhar P, Mccarthy S, Nagy P, Neubert A, Roberts S, Sayal K, Sonuga-Barke E, Wong Ick, Xia J, Zuddas A, Hollis C, Konrad K, Liddle Eb; Adduce Consortium. Neurological and psychiatric adverse effects of long-term methylphenidate treatment in adhd: a map of the current evidence. *Neurosci Biobehav Rev*. 2019; 107:945-968. doi: 10.1016/j.neubiorev.2019.09.023.
28. Mccarthy S, Neubert A, Man Kkc, Banaschewski T, Buitelaar J, **Carucci S**, Coghill D, Danckaerts M, Falissard B, Garas P, Häge A, Hollis C, Inglis S, Kovshoff H, Liddle E, Mechler K, Nagy P, Rosenthal E, Schlack R, Sonuga-Barke E, Zuddas A, Wong Ick. Effects of long-term methylphenidate use on growth and blood pressure: results of the german health interview and examination survey for children and adolescents (KIGGS). *BMC Psychiatry*. 2018 Oct 11;18(1):327
29. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes Aj, **Carucci S**, Atkinson Lz, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen Hc, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry*. 2018 Sep;5(9):727-738.
30. Balia C\*, **Carucci S\***, Coghill D, Zuddas A. The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication? *Neurosci Biobehav Rev*. 2018 Aug;91:218-238.
31. Mahdi S, Albertowski K, Almodayfer O, Arsenopoulou V, **Carucci S**, Dias Jc, Khalil M, Knüppel A, Langmann A, Lauritsen Mb, Da Cunha Gr, Uchiyama T, Wolff N, Selb M, Granlund M, De Vries Pj, Zwaigenbaum L, Bölte S. An international clinical study of ability and disability in autism spectrum disorder using the who-icf framework. *J Autism Dev Disord*. 2018 Jun;48(6):2148-2163.
32. Man Kkc, Coghill D, Chan Ew, Lau Wcy, Hollis C, Liddle E, Banaschewski T, Mccarthy S, Neubert A, Sayal K, Ip P, Schuemie Mj, Sturkenboom Mcjm, Sonuga-Barke E, Buitelaar J, **Carucci S**, Zuddas A, Kovshoff H, Garas P, Nagy P, Inglis Sk, Konrad K, Häge A, Rosenthal E, Wong Ick. Association of risk of suicide attempts with methylphenidate treatment. *JAMA Psychiatry*. 2017 Oct 1;74(10):1048-1055.

33. Hennissen L, Bakker Mj, Banaschewski T, **Carucci S**, Coghill D, Danckaerts M, Dittmann Rw, Hollis C, Kovshoff H, Mccarthy S, Nagy P, Sonuga-Barke E, Wong Ic, Zuddas A, Rosenthal E, Buitelaar Jk; Adduce Consortium. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with adhd: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. *CNS Drugs*. 2017 Mar;**31(3)**:199-215.
34. Inglis Sk, **Carucci S**, Garas P, Häge A, Banaschewski T, Buitelaar Jk, Dittmann Rw, Falissard B, Hollis C, Kovshoff H, Liddle E, Mccarthy S, Nagy P, Neubert A, Rosenthal E, Sonuga-Barke E, Wong I, Zuddas A, Coghill Dc; Adduce Consortium. Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the attention deficit hyperactivity disorder drugs use chronic effects (ADDUCE) study. *BMJ Open*. 2016 Apr **26**;6(4):e010433
35. Kovshoff H, Banaschewski T, Buitelaar Jk, **Carucci S**, Coghill D, Danckaerts M, Dittmann Rw, Falissard B, Grimshaw Dg, Hollis C, Inglis S, Konrad K, Liddle E, Mccarthy S, Nagy P, Thompson M, Wong Ic, Zuddas A, Sonuga-Barke Ej. Reports of perceived adverse events of stimulant medication on cognition, motivation, and mood: qualitative investigation and the generation of items for the medication and cognition rating scale. *J Child Adolesc Psychopharmacol*. 2016 Mar **23**.
36. Glennon J1, Purper-Ouakil D, Bakker M, Zuddas A, Hoekstra P, Schulze U, Castro-Fornieles J, Santosh Pj, Arango C, Kölch M, Coghill D, Flamarique I, Penzol Mj, Wan M, Murray M, Wong Ic, Danckaerts M, Bonnot O, Falissard B, Masi G, Fegert Jm, Vicari S, **Carucci S**, Dittmann Rw, Buitelaar Jk; The Pers Consortium. paediatric european risperidone studies (PERS): context, rationale, objectives, strategy, and challenges. *Eur Child Adolesc Psychiatry*. 2013 Dec **15**.
37. **Carucci S.**, Zuddas A. Managing Adhd Across Europe: The Italian View. *ADHD in practice* 2011; **3 (2)**:14-16.
38. Atzori P, Usala T., **Carucci S.**, Danjou F., Zuddas A. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. *Journal of Child and Adolescent Psychopharmacology* 2009, **19(6)**:673-81.

## PROTOCOLS

1. CARNOVALE C, BATTINI V, **CARUCCI S**, RICCIO MP, POZZI M, PISANO S. Association between the use of antipsychotic drugs and alterations of the parameters defining the metabolic syndrome (mets) in children and adolescents: an umbrella review. *Published In Prospero International prospective register of systematic reviews in date 5 June 2021*
2. SAMUELE CORTESE, **SARA CARUCCI**, CINZIA DEL GIOVANE, MARIANNA PURGATO, CORRADO BARBUI, ANDREA CIPRIANI, FARHAD SHOKRANEH, JUN XIA, TOBIAS BANASCHEWSKI, JAN BUITELAAR, DAVID COGHILL, RALF DITTMANN, MAITE FERRIN, CHRIS HOLLIS, MICHEL LECENDREUX, PARAMELA SANTOSH, EDMUND SONUGA-BARKE, CESAR SOUTULLO, ARGYRIS STRINGARIS, EMILY SIMONOFF, ERIC TAYLOR, IAN WONG, JOE SERGEANT, ALESSANDRO ZUDDAS ON BEHALF OF THE EUROPEAN ADHD GUIDELINES GROUP (EAGG). Comparative efficacy and tolerability of medications for attention-deficit/hyperactivity disorder: a multiple treatment meta-analysis. *Published In Prospero International prospective register of systematic reviews in date 16 March 2014*

## BOOK CHAPTERS

1. ZUDDAS, A., & **CARUCCI, S.** (2023). Therapeutic Use of Dopamine Enhancers (Stimulants). *Tasman's psychiatry* (5<sup>th</sup> edition). Springer
2. ZUDDAS, A., BALIA C., CARUCCI, S. (2024, update of 2020). Management and treatment of attention-deficit/hyperactivity disorder. In: J.R. Geddes, N.C. Andreasen, & G.M. Goodwin (Eds.). *New Oxford Textbook of Psychiatry* (3 ed., pp. 344-355). Oxford: Oxford University Press.

3. ZUDDAS, A., & **CARUCCI, S.** (2020). Management and treatment of attention-deficit/hyperactivity disorder. In: J.R. Geddes, N.C. Andreasen, & G.M. Goodwin (Eds.). *New Oxford Textbook of Psychiatry* (3 ed., pp. 344-355). Oxford: Oxford University Press.
4. **CARUCCI S.**, PABA S., DI MARTINO A., ZUDDAS A. Neuropsychiatric diseases of the basal ganglia: obsessive compulsive disorder, ADHD and Tourette Syndrome Neurobiology. In: D. Riva et al. (eds), Mariani Foundation Pediatric Neurology Series: Localization of brain lesions and developmental functions. John Libbey Eurotext 2009.

#### PAPERS IN ITALIAN

1. ZARRA M., PISANU L, RIZZI M, **CARUCCI S**, VENTURA G, CAVALLO R, GAGLIANO A. I disturbi specifici dell'apprendimento (DSA). *Medico e Bambino* 2024; 27(8):e150-e159 DOI: 10.53126/MEBXXVIIIO150
2. **CARUCCI S.** Come la ricerca deve guidare le scelte terapeutiche nel trattamento dei disturbi dello spettro autistico. *Medico e Bambino* 2024;27(6):e98-e100 DOI: 10.53126/MEBXXVIIGU98
3. ONNIS A, **CARUCCI S.** Il disturbo post-traumatico da stress. *Medico e Bambino* 2023;42(7):451-454
4. GHIRIGATO E, CORONA F, COZZI G, **CARUCCI S**, BARBI E. Screening del funzionamento psicologico: l'ottavo segno. *Medico e Bambino* 2023;42(1):31-37
5. BAZZONI M, ADRAGNA C, **CARUCCI S.** Il risperidone. *Medico e Bambino* 2023;42(2):111-115
6. **CARUCCI S.** ADHD e metilfenidato: il progetto europeo ADDUCE (Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects). *Giornale di Neuropsichiatria dell'Età Evolutiva* 2023 43: 11-18.
7. **CARUCCI S.**, NARDUCCI C., BAZZONI M., BALIA C., DONNO F., GAGLIANO A. ZUDDAS A. Quali differenze di genere nell'ADHD? Caratteristiche cliniche, neuropsicologiche e dati di neuroimmagini. *Giornale di Neuropsichiatria dell'Età Evolutiva* 2022; 42:51-56
8. **CARUCCI S.** Metilfenidato e ADHD. *Medico e Bambino* 2021;40(5):325-328
9. **CARUCCI S.** Psicoterapia a indirizzo cognitivo-comportamentale. *Medico e Bambino* 2020;39(3):177-178
10. **CARUCCI S.** ABA: l'analisi comportamentale applicata. *Medico e Bambino* 2020;39(8):527-528
11. **CARUCCI S**, CARTA A, ROMANIELLO R, ZUDDAS A. Effetti sulla crescita della terapia a lungo termine con metilfenidato in bambini e adolescenti con Disturbo da Deficit di Attenzione e Iperattività (ADHD). *Gior Neuropsich Età Evol* 2015;35:52-55
12. ZUDDAS A., PINTOR M., **CARUCCI S.** Psicopatologia e Psicofarmacologia in Età Evolutiva. *Facts News & Views* 2010; 10(2) :16-19
13. LECCA L., **CARUCCI S.**, ZUDDAS A. Neurobiologia della Depressione in Età Evolutiva. *Psichiatria dell'infanzia e dell'adolescenza* 2008; 75(3-4) :192

#### BOOK CHAPTERS IN ITALIAN

1. **CARUCCI S.**, BALIA C., GAGLIANO A., ZUDDAS A. Eziologia e fisiopatologia. ADHD nell'adulto. Dalla diagnosi al trattamento. (a cura di) Mencacci, C., Migliarese, G. (2021). Edizioni Edra, Milano.
2. **CARUCCI S.** Il disturbo oppositivo provocatorio. Cap. 29 – In *Manuale di Neuropsichiatria Infantile e dell'Adolescenza*. A cura di Antonio M. Persico. SEU Roma 2018

3. MASI G., ZUDDAS A, **CARUCCI S**, BALIA C, MILONE AR, PFANNER C, MANFREDI. ADHD forme di maggiore complessità diagnostica. In Profili cognitivi e disturbi psicopatologici. 2018 Edizioni Centro Studi Erickson S.p.A.

  
**Signature: Sara Carucci**

**Date: 11 may 2025**